{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:49:33Z","timestamp":1792003773615,"version":"4.4.0"},"reference-count":23,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Gastro and Hepatol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      Tegoprazan is a novel potassium\u2010competitive acid blocker (P\u2010CAB) used to treat acid\u2010related diseases. This study aimed to evaluate the effect of the\n                      <jats:styled-content style=\"fixed-case\">\n                        <jats:italic>H. pylori<\/jats:italic>\n                      <\/jats:styled-content>\n                      infection status on the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics and safety of tegoprazan.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This study involved two cohorts. In Cohort 1, 12\n                      <jats:styled-content style=\"fixed-case\">\n                        <jats:italic>H. pylori<\/jats:italic>\n                      <\/jats:styled-content>\n                      \u2010negative subjects were administered tegoprazan at 50 or 100\u2009mg for 7\u2009days. In Cohort 2, four subjects positive for\n                      <jats:styled-content style=\"fixed-case\">\n                        <jats:italic>H. pylori<\/jats:italic>\n                      <\/jats:styled-content>\n                      received 50 and 100\u2009mg of tegoprazan in a single dose crossover study. We estimated the PK parameters using non\u2010compartment analysis and measured PD parameters using an intragastric pH monitor.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The PK and PD of tegoprazan in both groups were dose\u2010dependent. The\n                      <jats:italic>C<\/jats:italic>\n                      <jats:sub>max<\/jats:sub>\n                      of each dose of tegoprazan in subjects with\n                      <jats:styled-content style=\"fixed-case\">\n                        <jats:italic>H. pylori<\/jats:italic>\n                      <\/jats:styled-content>\n                      decreased more than in the\n                      <jats:styled-content style=\"fixed-case\">\n                        <jats:italic>H. pylori<\/jats:italic>\n                      <\/jats:styled-content>\n                      negative group, but the AUC\n                      <jats:sub>last<\/jats:sub>\n                      and AUC\n                      <jats:sub>inf<\/jats:sub>\n                      of the two groups were similar. All PD parameters in\n                      <jats:styled-content style=\"fixed-case\">\n                        <jats:italic>H. pylori<\/jats:italic>\n                      <\/jats:styled-content>\n                      \u2010positive subjects increased more than in the negative group, which suggests that tegoprazan's intragastric acid suppression is enhanced in cases of\n                      <jats:styled-content style=\"fixed-case\">\n                        <jats:italic>H. pylori<\/jats:italic>\n                      <\/jats:styled-content>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The presence of\n                      <jats:styled-content style=\"fixed-case\">\n                        <jats:italic>H. pylori<\/jats:italic>\n                      <\/jats:styled-content>\n                      did not have a clinically significant effect on tegoprazan's PK and tolerability, but significantly enhanced its intragastric acid suppression efficacy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jgh.70671","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T08:15:23Z","timestamp":1788164123000},"page":"3101-3108","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacokinetic and Pharmacodynamic Characteristics of Tegoprazan According to\n                    <i>Helicobacter pylori<\/i>\n                    Infection Status"],"prefix":"10.1111","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4674-7682","authenticated-orcid":false,"given":"Sungpil","family":"Han","sequence":"first","affiliation":[{"name":"Department of Pharmacology, College of Medicine The Catholic University of Korea  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heechan","family":"Lee","sequence":"additional","affiliation":[{"name":"Clinical Development HK inno.N Corp.  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seokuee","family":"Kim","sequence":"additional","affiliation":[{"name":"Clinical Development HK inno.N Corp.  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee\u00a0Youn","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, College of Medicine University of Ulsan  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yo\u00a0Han","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, College of Medicine University of Ulsan  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji\u00a0Yeon","family":"Nam","sequence":"additional","affiliation":[{"name":"Clinical Development HK inno.N Corp.  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bongtae","family":"Kim","sequence":"additional","affiliation":[{"name":"Clinical Development HK inno.N Corp.  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geun\u00a0Seog","family":"Song","sequence":"additional","affiliation":[{"name":"Clinical Development HK inno.N Corp.  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeong\u2010Seok","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, College of Medicine University of Ulsan  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7399-5879","authenticated-orcid":false,"given":"Kyun\u2010Seop","family":"Bae","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, College of Medicine University of Ulsan  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1586\/ecp.09.8"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(03)00015-9"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2018.1461835"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-010-1209-2"},{"key":"e_1_2_8_6_1","article-title":"Nocturnal Acid Breakthrough\u2014Approach to Management","volume":"6","author":"Tutuian R.","year":"2004","journal-title":"MedGenMed"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.5009\/gnl15502"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.5056\/jnm18029"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0000000000000543"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.244202"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15438"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.12793\/tcp.2019.27.2.80"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12958"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-020-00986-4"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15480"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.36.4.539"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00531.x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/003655299750025480"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2010.06408.x"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14148"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.48.2.157"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16121"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.02140.x"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9270(00)00775-9"}],"container-title":["Journal of Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jgh.70671","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jgh.70671","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jgh.70671","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:50:29Z","timestamp":1790848229000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jgh.70671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1111\/jgh.70671"],"URL":"https:\/\/doi.org\/10.1111\/jgh.70671","archive":["Portico"],"relation":{},"ISSN":["0815-9319","1440-1746"],"issn-type":[{"value":"0815-9319","type":"print"},{"value":"1440-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"assertion":[{"value":"2025-10-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}